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London, UKDuc H. Le1. Gut Microbiome and Inﬂammatory Bowel Disease cardiometabolic risk factors. In summary, strategies to modulateBidirectional brain-gut interactions are highly relevant in human
intestinal diseases such as irritable bowel syndrome (IBS), and pre-
clinical studies help shed light on its complexity. Dysbiosis of the
bacterial gut microbiome became apparent and microbiome modu-
lation is now considered an important target for treatment. To
study the pathology of IBS, Wouter J. de Jonge (Amsterdam, The
Netherlands) and colleagues employed animal models for stressful
early life events that are known to predispose to IBS at adult age.
Transplantation of microbiota from a visceral hypersensitive rat to
a normosensitive one transferred the phenotype, suggesting that
the microbiome is critical in the stress-induced hypersensitivity.
Furthermore, the authors addressed potential mechanisms by
which neural signals can affect host defense andmicrobiome compo-
sition in the gut lumen. T lymphocytes were found to be very respon-
sive to neuronal signals; and genetic knockout studies have revealed
a critical function of these T cells in regulating anti-microbial pep-
tides by intestinal epithelia. As such, the effect of stress and neuronal
activity could relay to host defense mechanisms of the gut epithelia
and microbial richness and diversity. Future studies are warranted
in the ﬁeld of microbiome adaptation for IBS pathology.
2. Modulation of Gut Microbiota in Obesity and Cardiometabolic
Disorders
Changes in gut microbiota are associated with metabolic disorders
such as obesity, type 2 diabetes and cardiovascular risk factors. Patrice
D. Cani (Brussels, Belgium), Willem M. de Vos (Wageningen, The
Netherlands) and collaborators have identiﬁed Akkermansiamuciniphila
as a potential target to treat cardiometabolic disorders and inﬂamma-
tion. A. muciniphila is a mucin-degrading bacterium living in the
gut's mucus layer. The authors demonstrated that feeding mice with
A. muciniphila reduced bodyweight, fat mass and inﬂammation, and
restored gut barrier function by acting on mucus layer thickness
and restoring the production of antimicrobial proteins. The authors
also showed that in obese people, the abundance of A. muciniphila was
inversely related to fasting plasma glucose levels, visceral fat accumula-
tion and adipocyte diameter in subcutaneous adipose tissue. Upon calo-
ric restriction, obese individuals with higher baseline A. muciniphila
showed improved insulin sensitivity markers and otherhttp://dx.doi.org/10.1016/j.ebiom.2016.04.035
2352-3964/© 2016 The Author. Published by Elsevier B.V. This is an open access article underA.muciniphila composition in the humangut to treat obesity and cardio-
metabolic disorders warrant further investigation.
3. Liver Diseases and Gut Microbiota
The hepatic portal vein conducts blood from the gastrointestinal
tract to the liver, carrying metabolites produced by the gut microbiota
making the liver one of the main organ that can be inﬂuenced by
microbiome composition and activities. Philippe Gérard (Jouy-en-
Josas, France) and collaborators demonstrated that a speciﬁc dysbiosis
in intestinal microbiota (IM) was associated with alcoholic liver disease
(ALD) severity in patients. The researchers transplanted germ-free and
conventionalmicewith human IM from alcoholic patientswith orwith-
out alcoholic hepatitis (AH). Mice receiving IM from an AH patient de-
veloped more severe liver inﬂammation with an increased number of
liver T and NK lymphocyte subsets, higher liver necrosis, greater intesti-
nal permeability and higher translocation of bacteria than mice harbor-
ing the IM from an alcoholic patient without AH (noAH). Distinct
differences in IM composition could be observed, with key deleterious
bacterial species being associated with AH and the Faecalibacterium
genus being associated with noAH. A subsequent transfer of IM from a
noAH patient could improve alcohol-induced liver lesions in conven-
tional mice previously transplanted with IM from an AH patient. In
conclusion, it may be possible to prevent and manage ALD by IM
manipulation.
4. Gut Microbiota in Cystic Fibrosis
Fiona Fouhy (Fermoy, Ireland) and colleagues in the CFMATTERS
project presented novel longitudinal data on the cystic ﬁbrosis (CF)
gutmicrobiota. The researchers examined the gutmicrobiota of individ-
uals with CF at stability, during pulmonary exacerbation and post exac-
erbation, and compared that to non-CF controls. DNA was extracted
from fecal samples and the 16S rRNA gene was sequenced on the
Illumina MiSeq platform. During exacerbation, changes in microbiota
at phylum, family and genus levels were detected before intravenous
antibiotic therapy, but the most dramatic changes in microbiota were
seen after therapy commencement. Functionality of the gut microbiota
was also interrogated using samples from 6 people with CF and 6 con-
trols, with shotgun metagenomic sequencing and metabolomicthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dation increased in the CF group compared to the controls. Metabolites
were also altered. This study highlights temporal changes in CF gut mi-
crobiota, metabolites and microbiota functionality.
5. Skin Microbiota in Health and Disease
While the gut microbiota is intensively investigated, knowledge
about the skin microbiota, its protective function and immunomodula-
tory properties remains limited. The skin microbiota of the face
and upper back is dominated by Staphylococcus and Propionibacterium
species; in particular, Propionibacterium acnes predominately colonizes
sebaceous areas. Using comparative genomics analysis, Holger
Brüggemann (Aarhus, Denmark) and colleagues revealed the multi-
phyletic composition of P. acne; certain P. acnes phylotypes are associat-
ed with healthy skin while others are associated with skin disorders
such as acne vulgaris and progressive macular hypomelanosis. Confocal
microscopy revealed the colonization pattern of P. acnes within the
lumen of sebaceous follicles; healthy skin contained an organized,
bioﬁlm-like network of bacteria that does not seem to get in close con-
tact with the adjacent keratinocyte layer. In contrast, in acne-affected
skin, P. acnes was found to be tightly associated to skin cells,
which might lead to the activation of innate immune responses. Thedata highlighted the fragile balance between P. acnes and the skin mi-
croenvironment, and a dysbiosis in P. acnes phylotype composition
may lead to skin disorders.6. Skin andHair Aging, Lifestyle and the Skin and ScalpMicrobiomes
William W. Mohn (Vancouver, Canada) reported on a cross-
sectional study investigating the skin and scalp microbiome in relation
to skin and hair aging and lifestyle, and involving 495 subjects
10–78 years of age. Diversity of the scalp microbiome increased with
age, but its overall compositionwas not correlatedwith age. The reverse
was true of the foreheadmicrobiome. The authors also showed that spe-
ciﬁcmicrobial populationswere correlatedwith visible signs of skin and
hair aging and lifestyle factors. Many forehead populationswere associ-
ated with age and, more weakly, with age-related characteristics like
periorbital wrinkling and facial hyperpigmentation, while the reverse
was true for scalp populations. Overall, facial skin and scalp have distinct
microbiome communities uniquely associated with skin and hair aging
and lifestyle factors. Two Corynebacterium populations exhibited a strik-
ing pattern of co-exclusion on both the forehead and scalp. One popula-
tion was abundant on most subjects in younger age classes, but it
appeared to be completely displaced by the other during middle age.
